In this cohort study of 3665 patients with CHB without cirrhosis, HCC incidence was significantly lower in patients treated with antiviral therapy in both ALT groups <2 × ULN or ≥2 × ULN following comprehensive adjustment for background risks with the previously validated REACH-B HCC risk score. The gene discussed is GPT; the disease is hepatocellular carcinoma.